TScan Therapeutics Inc

NAS:TCRX (USA)  
$ 7.96 -0.345 (-4.16%) 01:23 PM EST
At Loss
P/B:
2.53
Market Cap:
$ 380.90M
Enterprise V:
$ 299.97M
Volume:
127.79K
Avg Vol (2M):
164.59K
Volume:
127.79K
At Loss
Avg Vol (2M):
164.59K

Business Description

TScan Therapeutics Inc
NAICS : 541714 SIC : 2834
ISIN : US89854M1018
Description
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 2.08
Equity-to-Asset 0.55
Debt-to-Equity 0.61
Debt-to-EBITDA -1.15
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.37
Distress
Grey
Safe
Beneish M-Score -2.45
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 86.02
9-Day RSI 77.68
14-Day RSI 72.14
6-1 Month Momentum % 141.57
12-1 Month Momentum % 167.63

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.51
Quick Ratio 6.51
Cash Ratio 6.44
Days Sales Outstanding 553.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -26
Shareholder Yield % -14.6

Financials (Next Earnings Date:2024-05-10 Est.)

TCRX's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TCRX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

TScan Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 21.049
EPS (TTM) ($) -1.79
Beta 0
Volatility % 97
14-Day RSI 72.14
14-Day ATR ($) 0.569855
20-Day SMA ($) 7.147
12-1 Month Momentum % 167.63
52-Week Range ($) 1.62 - 9
Shares Outstanding (Mil) 47.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TScan Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

TScan Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

TScan Therapeutics Inc Frequently Asked Questions

What is TScan Therapeutics Inc(TCRX)'s stock price today?
The current price of TCRX is $7.96. The 52 week high of TCRX is $9.00 and 52 week low is $1.62.
When is next earnings date of TScan Therapeutics Inc(TCRX)?
The next earnings date of TScan Therapeutics Inc(TCRX) is 2024-05-10 Est..
Does TScan Therapeutics Inc(TCRX) pay dividends? If so, how much?
TScan Therapeutics Inc(TCRX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1